Literature DB >> 23907328

[Deep brain stimulation. New target areas and new indications].

M M Reich1, A A Kühn, J Volkmann.   

Abstract

Many patients with neurological movement disorders and psychiatric diseases cannot yet be adequately treated with conventional methods. Deep brain stimulation represents an important extension of therapeutic options by which invasive electrodes are implanted in various subcortical brain areas in order to achieve an improvement in motor and psychiatric symptoms by high frequency stimulation. Up to 2012 approximately 100,000 patients had been treated with deep brain stimulation worldwide. The indications for deep brain stimulation were essentially already established indications, such as idiopathic Parkinson's syndrome, dystonia and tremors. The newer indications which include in particular psychiatric symptoms, such as depression, obsessive diseases, addiction and Tourette syndrome, are as yet limited to approximately 5 % of treated patients. An increasingly better understanding of the system physiology of neurological and psychiatric diseases has promoted the search for new target areas and indications for treatment by neuromodulation. This article gives an overview of the latest developments in the established and also the developing application areas of deep brain stimulation.

Entities:  

Mesh:

Year:  2013        PMID: 23907328     DOI: 10.1007/s00115-013-3757-0

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  56 in total

1.  Combined pedunculopontine-subthalamic stimulation in Parkinson disease.

Authors:  S Khan; S S Gill; L Mooney; P White; A Whone; D J Brooks; N Pavese
Journal:  Neurology       Date:  2012-03-07       Impact factor: 9.910

2.  Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.

Authors:  Eugénie Lhommée; Hélène Klinger; Stéphane Thobois; Emmanuelle Schmitt; Claire Ardouin; Amélie Bichon; Andrea Kistner; Valérie Fraix; Jing Xie; Magaly Aya Kombo; Stephan Chabardès; Eric Seigneuret; Alim-Louis Benabid; Patrick Mertens; Gustavo Polo; Sebastien Carnicella; Jean-Louis Quesada; Jean-Luc Bosson; Emmanuel Broussolle; Pierre Pollak; Paul Krack
Journal:  Brain       Date:  2012-04-15       Impact factor: 13.501

3.  Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years.

Authors:  Sidney H Kennedy; Peter Giacobbe; Sakina J Rizvi; Franca M Placenza; Yasunori Nishikawa; Helen S Mayberg; Andres M Lozano
Journal:  Am J Psychiatry       Date:  2011-02-01       Impact factor: 18.112

4.  Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease.

Authors:  Alessandro Stefani; Andres M Lozano; Antonella Peppe; Paolo Stanzione; Salvatore Galati; Domenicantonio Tropepi; Mariangela Pierantozzi; Livia Brusa; Eugenio Scarnati; Paolo Mazzone
Journal:  Brain       Date:  2007-01-24       Impact factor: 13.501

5.  Long-term effects of nucleus accumbens deep brain stimulation in treatment-resistant depression: evidence for sustained efficacy.

Authors:  Bettina H Bewernick; Sarah Kayser; Volker Sturm; Thomas E Schlaepfer
Journal:  Neuropsychopharmacology       Date:  2012-04-04       Impact factor: 7.853

6.  Surgical therapy for multiple sclerosis tremor: a 12-year follow-up study.

Authors:  A Hassan; J E Ahlskog; M Rodriguez; J Y Matsumoto
Journal:  Eur J Neurol       Date:  2012-01-17       Impact factor: 6.089

7.  Long term follow-up of deep brain stimulation of the caudal zona incerta for essential tremor.

Authors:  Anders Fytagoridis; Ulrika Sandvik; Mattias Aström; Tommy Bergenheim; Patric Blomstedt
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-12-28       Impact factor: 10.154

8.  Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease.

Authors:  Kenneth A Follett; Frances M Weaver; Matthew Stern; Kwan Hur; Crystal L Harris; Ping Luo; William J Marks; Johannes Rothlind; Oren Sagher; Claudia Moy; Rajesh Pahwa; Kim Burchiel; Penelope Hogarth; Eugene C Lai; John E Duda; Kathryn Holloway; Ali Samii; Stacy Horn; Jeff M Bronstein; Gatana Stoner; Philip A Starr; Richard Simpson; Gordon Baltuch; Antonio De Salles; Grant D Huang; Domenic J Reda
Journal:  N Engl J Med       Date:  2010-06-03       Impact factor: 91.245

9.  Neurostimulation for Parkinson's disease with early motor complications.

Authors:  W M M Schuepbach; J Rau; K Knudsen; J Volkmann; P Krack; L Timmermann; T D Hälbig; H Hesekamp; S M Navarro; N Meier; D Falk; M Mehdorn; S Paschen; M Maarouf; M T Barbe; G R Fink; A Kupsch; D Gruber; G-H Schneider; E Seigneuret; A Kistner; P Chaynes; F Ory-Magne; C Brefel Courbon; J Vesper; A Schnitzler; L Wojtecki; J-L Houeto; B Bataille; D Maltête; P Damier; S Raoul; F Sixel-Doering; D Hellwig; A Gharabaghi; R Krüger; M O Pinsker; F Amtage; J-M Régis; T Witjas; S Thobois; P Mertens; M Kloss; A Hartmann; W H Oertel; B Post; H Speelman; Y Agid; C Schade-Brittinger; G Deuschl
Journal:  N Engl J Med       Date:  2013-02-14       Impact factor: 91.245

10.  Pallidal deep brain stimulation in patients with primary generalised or segmental dystonia: 5-year follow-up of a randomised trial.

Authors:  Jens Volkmann; Alexander Wolters; Andreas Kupsch; Jörg Müller; Andrea A Kühn; Gerd-Helge Schneider; Werner Poewe; Sascha Hering; Wilhelm Eisner; Jan-Uwe Müller; Günther Deuschl; Marcus O Pinsker; Inger-Marie Skogseid; Geir Ketil Roeste; Martin Krause; Volker Tronnier; Alfons Schnitzler; Jürgen Voges; Guido Nikkhah; Jan Vesper; Joseph Classen; Markus Naumann; Reiner Benecke
Journal:  Lancet Neurol       Date:  2012-11-01       Impact factor: 44.182

View more
  2 in total

Review 1.  [Anesthesiological management of awake craniotomy : Asleep-awake-asleep technique or without sedation].

Authors:  M Seemann; N Zech; B Graf; E Hansen
Journal:  Anaesthesist       Date:  2015-02       Impact factor: 1.041

2.  Long-Latency Somatosensory Evoked Potentials of the Subthalamic Nucleus in Patients with Parkinson's Disease.

Authors:  Carlos Trenado; Saskia Elben; Lena Friggemann; Sonja Gruhn; Stefan Jun Groiss; Jan Vesper; Alfons Schnitzler; Lars Wojtecki
Journal:  PLoS One       Date:  2017-01-12       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.